Clinical trial · Observational
Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer
Implementation of Electroporation - NanoKnife as Treatment for Advanced Pancreatic Cancer.
NCT02079623CI-TRIAL-00042702NanoKnifecompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim for this study is to implement electroporation therapy (NanoKnife) treatment for patients with locally advanced pancreatic cancer. Electroporation therapy (NanoKnife) will be given in addition to standard chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electroporation/ Nano knife treatment | Procedure | — | UNRESOLVED |
| NanoKnife | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pancreatic cancer
- description
- Patients with locally advanced pancreatic cancer.
- interventionNames
- Procedure: Electroporation/ Nano knife treatment
- Device: NanoKnife
Primary outcomes (1)
- measure
- Tumor response
- timeFrame
- 24 months follow-up
- description
- According to RECIST criteria (PET-CT)
Secondary outcomes (2)
- measure
- CA-19-9
- timeFrame
- 24 months follow up
- description
- CA-19-9 measurement every 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients above 18 years old, who have given informed consent to treatment with electroporation 2. Performance status \<= 2 and meets one of the items below 3. Patients diagnosed with LAPC, who are not candidate to primary curative surgical treatment due to tumor invasion in surrounding blood vessels or adjacent organs 4. Patients, who have received oncological treatment with the aim of downstaging and the tumor still is deemed none-resectable Exclusion Criteria: 1. Patients with pacemaker or similar electrostimulator (TNS, anal sphincter stimulators ect.) 2. Patients for whom the anesthesia involves high risk (ASA- IV) 3. Estimated survival of less than 3 months 4. Metallic stent in the biliary tract, which can not be removed or changed to plastic stent. 5. Performance status \> 2. 6. Pregnancy 7. Epilepsy or other condition involving convulsions 8. Inability to give informed consent. 9. Patients with inability to cooperate for treatment and follow-up 10. Severe heart disease 11. Patients with a tumor larger than 5 cm.
References
Publications (0)
Data not yet available
No reference posted for this study.